Next 10 |
home / stock / adpt / adpt articles
U.S. stock futures were lower this morning, with the Nasdaq futures declining over 100 points on Friday. Shares of Netflix, Inc. (NASDAQ:NFLX) fell...
Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today's pre-market trading after the company reported a year-over-year incr...
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that ai...
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced Tuesday, April 3, that after a strategic review, the company will operate two busines...
SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that ai...
SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that ai...
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aim...
SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aim...
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aim...
News, Short Squeeze, Breakout and More Instantly...
Adaptive Biotechnologies Corporation Company Name:
ADPT Stock Symbol:
NASDAQ Market:
Adaptive Biotechnologies Corporation Website:
2024-05-08 18:43:24 ET Adaptive Biotechnologies (NASDAQ: ADPT) , a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the cure for the stock market blahs on Wednesday. The commercia...
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...